Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase III Clinical Development in CHINA

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Shanghai Junshi Biosciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

              Contact the Supplier

              Lead Product(s): Toripalimab

              Therapeutic Area: Oncology Product Name: JS001

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: AstraZeneca PLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 01, 2021

              Details:

              Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas.

              Shanghai Junshi Biosciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              NMPA Approves Toripalimab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma Who Faild at Least Two Lines of Systemic Therapy

              Contact the Supplier

              Lead Product(s): Toripalimab

              Therapeutic Area: Oncology Product Name: JS001

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 21, 2021

              Details:

              First approval of immune checkpoint blockade therapy in NPC in the world and the second approved indication for toripalimab in China.

              Innovent Biologics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Innovent Reports 1st Patient Dosed in Phase III Pivotal Trial of IBI310 Combined with TYVYT for First-line Advanced Hepatocellular Carcinoma

              Contact the Supplier

              Lead Product(s): Ipilimumab,Sintilimab

              Therapeutic Area: Oncology Product Name: IBI310

              Highest Development Status: Phase III